Nurix Therapeutics Inc (NAS:NRIX)
$ 21.49 -0.62 (-2.8%) Market Cap: 1.52 Bil Enterprise Value: 1.15 Bil PE Ratio: 0 PB Ratio: 3.82 GF Score: 48/100

Nurix Therapeutics Inc Annual Shareholders Meeting Transcript

May 04, 2023 / 04:00PM GMT
Release Date Price: $9.44 (+0.85%)
Arthur Sands
Nurix Therapeutics, Inc. - President, CEO, & Director

Good morning. This is Arthur Sands, President and Chief Executive Officer of Nurix Therapeutics. I would like to welcome you to Nurix's 2023 Annual Meeting of Stockholders. It is 9 AM Pacific Time on Thursday, May 4, 2023, and this meeting is officially called to order.

At Nurix, our mission is to bring breakthrough treatments to patients using targeted protein modulation. We have led the way in this new emerging field of science and medicine as experts in E3 ligases, a major new drug target class. We've been very successful in advancing new molecules into the clinic, with currently have three drug programs in Phase 1; two in leukemia and lymphoma, and one with the potential to address a wide spectrum of human tumors by optimizing activity of the immune system.

We continue to add to both our own and our partners' pipelines with new programs, the most recent being a new IRAK4 degrader license by Gilead last quarter, which triggered a $20 million license payment under our drug discovery alliance with Gilead, which

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot